Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
TNF-α Inhibitor (Fusion Protein) Pregnancy: Should only be used during pregnancy if clearly needed; women of childbearing potential should consider contraception during therapy and for three weeks after discontinuation; live vaccines to exposed infants generally not recommended for 16 weeks after mother's last dose (UK SPC §4.6)

Etanercept

Brand names: Enbrel, Benepali, Erelzi

Etanercept is a subcutaneous biological disease-modifying agent (a soluble TNF receptor fusion protein) used in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis and plaque psoriasis.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 25 mg twice weekly, or 50 mg once weekly
Route: SC
Frequency: Twice weekly (25 mg) or once weekly (50 mg)
UK SPC (Benepali, biosimilar); treatment initiated and supervised by a specialist. Rheumatoid arthritis: 25 mg twice weekly is recommended; alternatively 50 mg once weekly. Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis: 25 mg twice weekly or 50 mg once weekly; clinical response usually within 12 weeks. Plaque psoriasis: 25 mg twice weekly or 50 mg once weekly; alternatively 50 mg twice weekly for up to 12 weeks then 25 mg twice weekly or 50 mg once weekly; continue until remission, up to 24 weeks; discontinue if no response after 12 weeks. Paediatric dosing is weight-based: patients under 62.5 kg dosed on a mg/kg basis. Paediatric plaque psoriasis (age 6 years and above): 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to 24 weeks. Not established in children under 2 years. Clinician to verify paediatric dosing against a children's formulary.

Paediatric dose

Dose: 0.4 mg/kg
Route: SC
Frequency: Twice weekly (interval 3-4 days between doses); alternatively 0.8 mg/kg once weekly
Max: 25 mg per dose (or 50 mg per dose for the 0.8 mg/kg once-weekly regimen)
Juvenile idiopathic arthritis, UK SPC: 0.4 mg/kg (up to a maximum of 25 mg per dose) given twice weekly with a 3-4 day interval, OR 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly. Discontinue if no response after 4 months. A 10 mg vial strength may be more appropriate for children below 25 kg; safety/efficacy not established under 2 years. Verify against a children's formulary.

Dose adjustments

Renal

No dose adjustment required for renal or hepatic impairment

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

Juvenile idiopathic arthritis, UK SPC: 0.4 mg/kg (up to a maximum of 25 mg per dose) given twice weekly with a 3-4 day interval, OR 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly. Discontinue if no response after 4 months. A 10 mg vial strength may be more appropriate for children below 25 kg; safety/efficacy not established under 2 years. Verify against a children's formulary.

Verify in a children's formulary

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients
  • Sepsis or risk of sepsis
  • Active infections, including chronic or localised infections (do not initiate)

Side effects

  • Injection site reactions (pain, swelling, itching, reddening, bleeding)
  • Infections (upper respiratory tract infection, bronchitis, cystitis, skin infection) — very common
  • Headache
  • Allergic reactions and autoantibody formation
  • Serious infections/sepsis, malignancies (including lymphoma), and haematological reactions (e.g. pancytopenia, rare aplastic anaemia)

Interactions

  • Live vaccines (avoid concurrent administration)
  • Anakinra (increased risk of serious infection)
  • Abatacept (increased risk of serious adverse events, including infections)
  • Cyclophosphamide (not recommended for use with etanercept)

Clinical monograph

How it works

It is a recombinant fusion of the TNF receptor with the Fc portion of human IgG that binds and neutralises tumour necrosis factor, reducing the inflammatory cascade in immune-mediated disease.

Prescribing in practice

  • It increases susceptibility to serious infection, including reactivation of latent tuberculosis, so screening for TB and other chronic infections is required before starting.
  • Live vaccines should be avoided during treatment, and the drug should be withheld during active serious infection.
  • Use with caution in demyelinating disorders and moderate-to-severe heart failure, where TNF inhibitors may worsen the condition.

Monitoring

Monitor for infection and review full blood count and clinical response periodically in line with shared-care arrangements.

Counselling the patient

  • Report signs of infection such as persistent fever, cough or weight loss promptly.
  • Do not have live vaccines without discussing them with your specialist team.
  • You will be taught aseptic technique for self-injection and safe storage in the fridge.

Evidence & guidelines

NICE guidance supports TNF inhibitors including etanercept for inflammatory arthritis with inadequate response to conventional disease-modifying therapy.

Reference: NICE TA130; TEMPO trial; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways